547 related articles for article (PubMed ID: 25598013)
1. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
Franciosi AN; McCarthy C; McElvaney NG
Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
3. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
5. A review of augmentation therapy for alpha-1 antitrypsin deficiency.
Mohanka M; Khemasuwan D; Stoller JK
Expert Opin Biol Ther; 2012 Jun; 12(6):685-700. PubMed ID: 22500781
[TBL] [Abstract][Full Text] [Related]
6. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
7. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
8. [Expert statement for augmentation therapy in patients with alpha-1 antitrypsin deficiency].
Köhnlein T; Schmidt-Scherzer K; Greulich T; Bals R
Pneumologie; 2014 Jul; 68(7):492-5. PubMed ID: 25006842
[TBL] [Abstract][Full Text] [Related]
9. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
[TBL] [Abstract][Full Text] [Related]
10. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
11. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
12. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.
Casas F; Blanco I; Martínez MT; Bustamante A; Miravitlles M; Cadenas S; Hernández JM; Lázaro L; Rodríguez E; Rodríguez-Frías F; Torres M; Lara B
Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067
[TBL] [Abstract][Full Text] [Related]
13. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency.
Chorostowska-Wynimko J; Barrecheguren M; Ferrarotti I; Greulich T; Sandhaus RA; Campos M
Int J Chron Obstruct Pulmon Dis; 2020; 15():345-355. PubMed ID: 32103933
[TBL] [Abstract][Full Text] [Related]
14. Augmentation therapy in alpha-1 antitrypsin deficiency.
Heresi GA; Stoller JK
Expert Opin Biol Ther; 2008 Apr; 8(4):515-26. PubMed ID: 18352854
[TBL] [Abstract][Full Text] [Related]
15. Delivery of Alpha-1 Antitrypsin to Airways.
Griese M; Scheuch G
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S346-51. PubMed ID: 27564672
[TBL] [Abstract][Full Text] [Related]
16. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route.
Hubbard RC; Crystal RG
Lung; 1990; 168 Suppl():565-78. PubMed ID: 2117165
[TBL] [Abstract][Full Text] [Related]
17. Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment.
Monk R; Graves M; Williams P; Strange C
COPD; 2013 Aug; 10(4):411-5. PubMed ID: 23537112
[TBL] [Abstract][Full Text] [Related]
18. Safety of biweekly α
Greulich T; Chlumsky J; Wencker M; Vit O; Fries M; Chung T; Shebl A; Vogelmeier C; Chapman KR; McElvaney NG;
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30237305
[TBL] [Abstract][Full Text] [Related]
19. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
20. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.
O'Brien ME; Fee L; Browne N; Carroll TP; Meleady P; Henry M; McQuillan K; Murphy MP; Logan M; McCarthy C; McElvaney OJ; Reeves EP; McElvaney NG
Thorax; 2020 Apr; 75(4):321-330. PubMed ID: 31959730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
